Modopar (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier and is converted into dopamine within the central nervous system. Benserazide blocks peripheral conversion of levodopa, ensuring more of the drug reaches the brain where it compensates for the dopamine deficiency characteristic of Parkinson's disease.

The appropriate dose of Modopar is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, age, renal function and any concurrent medications. Dosage titration follows a careful schedule to balance symptom control with the risk of side effects.

The safety of Modopar during pregnancy or lactation has not been established, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Modopar product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Modopar combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it generally provides stronger symptomatic relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Modopar tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments to maintain potency.

Modopar is taken orally, usually with a glass of water. It is often recommended to take the medication on an empty stomach, 30 minutes before or one hour after meals, to improve absorption. The exact timing and frequency are determined by the prescribing clinician.

Serious risks include the development of dyskinesia (involuntary movements), severe hypotension, psychiatric effects such as hallucinations, and rare but life‑threatening conditions like neuroleptic malignant syndrome. Patients should be monitored regularly for these events, and any sudden changes should be reported to a healthcare provider immediately.

Modopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors, and caution is advised for patients with severe cardiovascular disease, uncontrolled hypertension, or a history of malignant neuroleptic syndrome.